Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.
D000042:Absorption; D000293:Adolescent; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012138:Respiratory Therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013183:Sputum / Q000382:microbiology; D013997:Time Factors
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents